SAB Biotherapeutics (SABS) Construction in Progress (2021 - 2023)

SAB Biotherapeutics' (SABS) quarterly Construction in Progress came in at $329617.0 in Q1 2023, up 139.18% on a QoQ basis from $137811.0 in Q4 2022.

SAB Biotherapeutics (SABS) Construction in Progress (2021 - 2023) Analysis & Trends

SAB Biotherapeutics (SABS) has 3 years of Construction in Progress data on file, last reported at $329617.0 in Q1 2023.

Quarterly Construction in Progress changed N/A year-over-year to $329617.0 in Q1 2023, while the trailing twelve-month figure through Mar 2023 was $329617.0 (changed N/A YoY) and the FY2022 annual result came in at $137811.0, down 35.47% from the prior year.
Construction in Progress rose to $329617.0 in Q1 2023, from $137811.0 in the prior quarter.
In the past five years, Construction in Progress ranged from a high of $329617.0 in Q1 2023 to a low of $137811.0 in Q4 2022.
A 3-year average of $226997.3 and a median of $213564.0 in 2021 frame the typical range for Construction in Progress.
The widest YoY moves for Construction in Progress: up 35.47% in 2022, down 35.47% in 2022.
Tracing SABS's Construction in Progress over 3 years: stood at $213564.0 in 2021, then plunged by 35.47% to $137811.0 in 2022, then surged by 139.18% to $329617.0 in 2023.
The last three Construction in Progress figures came in at $329617.0 (Q1 2023), $137811.0 (Q4 2022), and $213564.0 (Q4 2021), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Construction in Progress (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	-
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	152.67 Mn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-
10	SAB Biotherapeutics	308.92 Mn	308.92 Mn	-	-

Download Data